Accordingly, phase 1 clinical trials based on NGF gene delivery to NBM proved that this approach has the potential to improve cognitive symptoms and modify neurological disease progression in AD patients (Tuszynski et al., 2005). This evidence concerns the gene NGF and Alzheimer disease.